Pembrolizumab, a PD-1 inhibitor, demonstrated antitumor activity in patients with high-risk BCG-unresponsive carcinoma in situ.
Trimodal therapy for patients with muscle-invasive bladder cancer is associated with worse cancer-specific and overall survival and higher costs compared with radical cystectomy.
In a study of patients receiving non-surgical treatment for localized upper tract urothelial carcinoma, radiation or chemotherapy provided no overall survival benefit.
Squamous cell carcinoma is associated with a 79% increased risk of death compared with urothelial carcinoma in patients with muscle-invasive bladder cancer, study finds.
Standardized mortality ratio highest for cancers of lung, head and neck, testes, bladder, Hodgkin lymphoma.
TICE BCG is indicated for the treatment and prophylaxis of carcinoma in situ of the urinary bladder and for the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection.
Smokers had poorer response to cisplatin-based neoadjuvant chemotherapy, higher recurrence risk.
Researchers found no significant difference in 30-day postoperative complications between patients who received neoadjuvant chemotherapy and those who did not.
Patients with muscle-invasive bladder cancer had a 22% decreased risk of disease progression if they received neoadjuvant rather than adjuvant chemotherapy, a study found.
Method evaluating cells collected from urine shows 94% diagnostic accuracy.
Overweight and obesity, diabetes, and postoperative complications increase the likelihood of being readmitted within 30 days of hospital discharge among radical cystectomy patients.
The goal of bladder health month is to encourage individuals to engage in dialogue with their healthcare providers about their symptoms and to empower them to actively participate in their care.
In a study, nearly 1 in 10 cancer patients on systemic therapy experienced an episode of acute kidney injury.
Promising results from clinical trials could encourage urologists to offer immunotherapy to their bladder cancer patients.
UGN-1 is an investigational formulation of mitomycin, delivered to patients using standard intravesical catheters.
Older patients benefit from treatment of superficial bladder cancer even if they have multiple chronic conditions, a new study suggests.
In a study, men with prostate cancer who received androgen deprivation therapy did not have a lower subsequent risk of developing bladder cancer.
Enhanced cystoscopy at the time of cystectomy and in the outpatient surveillance setting increases detection of high-grade NMIBC.
Finnish study of individuals with type 2 diabetes reveals a 17% and 42% higher incidence of bladder and kidney cancer, respectively, compared with the general population.
Higher rates of complete response observed in MIBC patients who received a dose-dense combination of methotrexate, vinblastine, doxorubicin, and cisplatin rather than the standard gemcitabine plus cisplatin or carboplatin.
New meta-analysis shows adjuvant intravesical gemcitabine and bacillus Calmette-Guérin do not differ significantly with respect to risk of recurrence, progression, and adverse events.
Among patients undergoing radical cystectomy, female sex is independently associated with a 21% increased odds of surgical site infections compared with male sex.
Widowed patients with bladder urothelial carcinoma have the worst 5-year cancer-specific survival rates among unmarried patients.
British investigators concluded that urine cytology misses a significant number of muscle-invasive bladder cancers.
Recurrence rate was 26.4% among patients who had overnight continuous saline irrigation following transurethral resection of bladder tumor vs 38.2% among those who did not.
The updates come after the Agency made the decision to limit the use of these agents as monotherapy in patients with metastatic urothelial cancer who have not received prior therapy and who have low expression of the protein programmed death ligand 1 (PD-L1).
Bladder preservation for MIBC is associated with a higher mortality rate and greater costs compared with radical cystectomy.
In a randomized study, patients who underwent robotic-assisted and open radical cystectomy had similar 2-year progression survival rates.
Females have worse disease-free, cancer-specific, overall survival versus males with bladder cancer.
In 2015, 69% of surgeries for prostate, bladder, and kidney cancer were performed with robotic assistance, a new meta-analysis shows.
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)